statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	7.418
EU - Europa	5.346
AS - Asia	3.422
SA - Sud America	294
Continente sconosciuto - Info sul continente non disponibili	57
AF - Africa	47
OC - Oceania	12
Totale	16.596

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	7.211
IT - Italia	2.552
SG - Singapore	1.158
UA - Ucraina	959
CN - Cina	723
VN - Vietnam	546
TR - Turchia	389
SE - Svezia	379
HK - Hong Kong	372
FI - Finlandia	300
DE - Germania	278
BR - Brasile	252
FR - Francia	246
IE - Irlanda	206
GB - Regno Unito	164
CA - Canada	141
RU - Federazione Russa	131
IN - India	86
MX - Messico	47
BD - Bangladesh	45
JP - Giappone	26
PL - Polonia	26
NL - Olanda	25
ZA - Sudafrica	19
ES - Italia	17
IQ - Iraq	16
BE - Belgio	14
AR - Argentina	13
AT - Austria	11
NZ - Nuova Zelanda	9
PK - Pakistan	9
CH - Svizzera	8
CO - Colombia	8
LT - Lituania	8
PY - Paraguay	8
CZ - Repubblica Ceca	7
NG - Nigeria	7
SA - Arabia Saudita	7
UZ - Uzbekistan	7
AE - Emirati Arabi Uniti	6
CR - Costa Rica	6
EG - Egitto	5
EU - Europa	5
KE - Kenya	5
MY - Malesia	5
TN - Tunisia	5
LB - Libano	4
PH - Filippine	4
RS - Serbia	4
AU - Australia	3
DZ - Algeria	3
KR - Corea	3
MA - Marocco	3
PE - Perù	3
VE - Venezuela	3
CL - Cile	2
DK - Danimarca	2
EC - Ecuador	2
GR - Grecia	2
HN - Honduras	2
JM - Giamaica	2
KH - Cambogia	2
MD - Moldavia	2
NP - Nepal	2
OM - Oman	2
PA - Panama	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AZ - Azerbaigian	1
BB - Barbados	1
BG - Bulgaria	1
BH - Bahrain	1
BY - Bielorussia	1
DO - Repubblica Dominicana	1
EE - Estonia	1
GL - Groenlandia	1
GT - Guatemala	1
GY - Guiana	1
ID - Indonesia	1
IL - Israele	1
JO - Giordania	1
MO - Macao, regione amministrativa speciale della Cina	1
MT - Malta	1
NI - Nicaragua	1
PS - Palestinian Territory	1
PT - Portogallo	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TW - Taiwan	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	16.545

Salva come PNG Salva come JPEG

Città	#
Milan	1.845
Jacksonville	724
San Jose	711
Singapore	658
Ashburn	555
Chandler	529
Fairfield	453
Hong Kong	362
Woodbridge	354
Wilmington	259
Council Bluffs	252
Princeton	245
Beijing	233
Ann Arbor	229
Izmir	229
Dallas	225
Nyköping	216
Dublin	206
Dearborn	194
Seattle	194
Houston	181
The Dalles	165
Dong Ket	155
Boardman	147
Cambridge	134
Rome	129
Lauterbourg	116
Como	103
Toronto	102
New York	97
San Mateo	92
Chicago	85
Los Angeles	73
Ho Chi Minh City	67
San Diego	55
Santa Clara	54
Hanoi	50
Helsinki	50
Orem	44
Guangzhou	39
Ogden	38
Chennai	36
Munich	36
São Paulo	30
Düsseldorf	29
London	28
Mexico City	27
Verona	23
Warsaw	23
Manchester	22
Pune	22
Tokyo	22
Hefei	21
Turku	16
Brooklyn	15
Nanjing	15
Shanghai	15
Johannesburg	13
Amsterdam	12
Brussels	12
Kunming	12
Da Nang	11
Montreal	11
San Francisco	11
Atlanta	10
Denver	10
Frankfurt am Main	10
Fuzhou	10
Hangzhou	10
Phoenix	10
Stockholm	10
Boston	9
Haiphong	9
Norwalk	9
Shenzhen	9
St Petersburg	9
Jinan	8
Poplar	8
Redwood City	8
Zhengzhou	8
Abuja	7
Baghdad	7
Christchurch	7
Curitiba	7
Mumbai	7
New Delhi	7
Ponte Lambro	7
Raleigh	7
Varese	7
Washington	7
Auburn Hills	6
Querétaro	6
Rozzano	6
Villanova D'asti	6
Can Tho	5
Changsha	5
Charlotte	5
Chongqing	5
Dhaka	5
Falls Church	5
Totale	11.382

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	226
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	219
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	211
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	208
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	206
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	206
The MHC class II transactivator: prey and hunter in infectious diseases	205
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	190
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	187
New strategies of mammary cancer vaccination	183
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	180
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	180
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	172
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	171
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	166
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	160
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	159
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	158
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	158
Analysis of microchimerism in thyroid autoimmune diseases	158
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	158
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	156
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	155
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	153
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	150
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay	150
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	149
The complex liaison between cachexia and tumor burden	148
MHC immunoevasins: protecting the pathogen reservoir in infection	147
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	147
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	147
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	146
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	146
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	145
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	145
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	145
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	145
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	145
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	144
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	143
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	142
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	142
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	141
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	141
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	140
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	140
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	140
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	139
The history of discovery of Interleukin-1: A fundamental cytokine of the innate immune response	138
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	137
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	136
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	136
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	134
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	131
Regulation of HLA antigen expression in HIV infected cells	131
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	131
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	129
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	128
Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells	128
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	127
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	127
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	127
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	125
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	124
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	124
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	124
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	122
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	120
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	120
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	120
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	119
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	119
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	119
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	119
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	118
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	117
Imaging guided percutaneous microwave ablation of tumors.	116
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	116
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	115
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	115
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	114
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	114
Regulation of HLA antigen expression in phagocytes with mycobacteria	114
Inhibition of HTLV-2 viral replication by the MHC class II transcriptional activator (CIITA)	114
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	114
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ	112
HLA-DQ expression is differently regulated from -DR and -DP	112
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	112
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	112
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	112
The complex liaison between vulnerability to cachexia and tumor burden.	111
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	110
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	110
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	109
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	109
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA	108
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	107
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat	106
Temporal and quantitative relations between CIITA and HLA class II expression	106
Totale	14.097

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	66.282
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	66.282

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	960	0	133	106	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.818	452	438	505	488	499	220	24	25	104	17	2	44
2024/2025	1.712	13	47	320	32	84	70	79	86	221	109	133	518
2025/2026	4.114	307	235	118	553	429	279	1.019	256	393	254	139	132
2026/2027	259	79	180	0	0	0	0	0	0	0	0	0	0
Totale													16.596